ReviewNature reviews. Clinical oncology2012
Tumour molecular profiling for deciding therapy-the French initiative.
Review in Nature reviews. Clinical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Precision oncology: transforming cancer care through personalized medicine.Medical oncology (Northwood, London, England) · 2025Review
- Framework for Adoption of Next-Generation Sequencing (NGS) Globally in the Oncology Area.Healthcare (Basel, Switzerland) · 2023Article
- E-prescription and invisible work in genomics in France.Frontiers in sociology · 2023Article
- OSIRIS: A Minimum Data Set for Data Sharing and Interoperability in Oncology.JCO clinical cancer informatics · 2021Article
- Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratories.British journal of cancer · 2018Article
- Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme.ESMO open · 2018Article
- Evaluation of pre-analytical conditions and comparison of the performance of several digital PCR assays for the detection of majorOncotarget · 2017Article
- High-throughput detection of clinically targetable alterations using next-generation sequencing.Oncotarget · 2017Article
- Implementation and Quality Control of Lung Cancer EGFR Genetic Testing by MALDI-TOF Mass Spectrometry in Taiwan Clinical Practice.Scientific reports · 2016Observational
- Equal access to innovative therapies and precision cancer care.Nature reviews. Clinical oncology · 2016Review
- Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.BMC cancer · 2016Article
- Observational
- Article
- Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe.Molecular oncology · 2014Review
- A catalyst for change: the European cancer Patient's Bill of Rights.The oncologist · 2014Article
- Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.Annals of oncology : official journal of the European Society for Medical Oncology · 2014Observational
- Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment.Clinical Medicine Insights. Oncology · 2014Article
- Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group.BMC cancer · 2013Article
- Article
- Computational purification of individual tumor gene expression profiles leads to significant improvements in prognostic prediction.Genome medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of tumour molecular profiles for therapeutic decision making requires that molecular diagnostics be introduced into routine clinical practice. To this end, the French National Cancer Institute and French Ministry of Health have set up a national network of 28 regional molecular genetics centres. These facilities perform selected molecular tests, free of charge, for all patients in their region, regardless of the institution where they are treated. A specific programme has also been implemented to anticipate the launch of new targeted treatments and reduce time-to-access to new drugs and experimental therapies. In 2011, 55,000 patients with cancer in France benefited from molecular predictive tests. The French nationwide initiative for tumour molecular profiling is a tool to fight inequalities in access to molecular testing and targeted therapy, and demonstrates that molecular stratification of tumours for therapeutic decisions is a cost-effective strategy that can be successfully integrated into the health-care system.
Indexed as
Identifiers
22777058What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.